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Tenofovir-disoproxil-fumarate (TDF) is a double ester prodrug which enables intestinal uptake of tenofovir 
(TFV) after oral administration in humans. In this study, prodrug stability was monitored in situ in the 
human intestine and in vitro using biorelevant media. In fasted state human intestinal fluids, the prodrug 
was completely degraded within 90 min, resulting in the formation of the mono-ester intermediate and 
TFV; in fed state intestinal fluids, the degradation rate of TDF was reduced and no TFV was formed. 
Intestinal fluid samples aspirated after administration of TDF confirmed extensive intraluminal 
degradation of TDF in fasted state conditions; a relatively fast absorption of TDF partly compensated for 
the degradation. Although food intake reduced intestinal degradation, the systemic exposure was not 
proportionally increased. The lower degradation in fed state conditions may be attributed to competing 
esterase substrates present in food, lower chemical degradation in the slightly more acidic environment 
and micellar entrapment, delaying exposure to the “degrading” intestinal environment. The results of this 
study demonstrate premature intestinal degradation of TDF and suggest that TFV may benefit from a 
more stable prodrug approach; however, fast absorption may compensate for fast degradation, indicating 




Tenofovir (TFV) is a nucleotide reverse transcriptase inhibitor which is used for the treatment of hepatitis 
B and HIV-infections. It is a very hydrophilic compound (logD7.4=-3.55) containing two negative charges 
resulting in low intestinal permeability; therefore, it is classified as a BCS class III compound. (Kearney et 
al., 2004) One of the strategies used to overcome permeability issues is to increase the lipophilicity of the 
compound through a prodrug strategy. A prodrug is an inactive form of the drug, which has to be 
activated once taken up. (Rautio et al., 2008) At this moment, TFV is on the market as the bis-ester 
prodrug tenofovir disoproxil fumarate (TDF, Viread®). In this prodrug, two isopropyloxycarbonyloxymethyl 
moieties mask the negative charges of TFV, to form a lipophilic ester prodrug that results in an increased 
transport across the intestinal epithelium. The prodrug is hydrolyzed in two steps: first, TDF is hydrolyzed 
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by carboxylesterases to the mono-ester intermediate; this intermediate is further hydrolyzed by 
phosphodiesterases to the active form TFV. (figure 1) These enzymes are present in the lumen of the 
intestine, coming from the secretion of the pancreas and from the enterocytes. Only the active form is 
observed in the systemic circulation. (Fardis and Oliyai, 2007) Compared to direct oral administration of 
TFV, intake of the prodrug results in a bioavailability increase of tenofovir from 2% to 20% in mice and 
from 17.1% to 30.1% in dogs. (Naesens et al., 1998); (Cundy et al., 1998) Although the bioavailability is 
increased, it remains relatively low. Premature degradation of the ester prodrug in the intestinal tract, 
either by chemical or by enzymatic hydrolysis, might contribute to the limited efficiency of the prodrug 
approach.  
 
The intestinal absorption behavior of TDF has been studied in different experimental set-ups including 
Caco-2 cells, in situ perfusion systems and cellular incubation systems. (Barditch-crovo et al., 2001); 
(Heimbach et al., 2003); (Roux et al., 2013); (Van Gelder et al., 1999) However, to the best of our 
knowledge, no in vivo data about the intestinal behavior of TDF has been collected yet. When reviewing 
the available in vitro data about the decomposition of TDF, contradictory observations have been 
reported. Roux et. al. found that decomposition of TDF resulted predominantly from chemical 
degradation: the decomposition rate (kc) amounted to 6.6 x 10-3 min-1 for the chemical degradation as 
compared to 1.1 x 10-3 min-1 for the enzymatic degradation (Roux et al., 2013). Lung-Chi et. al. further 
explored the influence of pH on the degradation kinetics of ester prodrugs containing an 
oxycarbonyloxymethyl group (including TDF) and concluded that these prodrugs are most stable in a pH 
range from 2 to 3. When increasing the pH above 3, they become exponentially more sensitive to 
chemical hydrolysis. (Lung-Chi et al., 2001) 
In contrast, Van Gelder et al. attributed TDF degradation during absorption primarily to the enzymatic 
pathway. By using homogenates of Caco-2 cells and intestinal homogenates from rat, pig and humans, a 
very fast esterase-mediated degradation of the ester-prodrug was observed. The role of esterases was 
confirmed by the fact that the degradation was inhibited by co-incubation with esterase inhibitors; 
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degradation was also decreased upon co-incubation with fruit extracts, suggesting competitive inhibition 
by the esters present in these extracts. (Van Gelder et al., 2002)  
The data so far suggest that chemical as well as enzymatic degradation may lead to a premature 
decomposition of TDF in the intestinal tract, resulting in a decreased availability of the prodrug and, 
eventually, reduced absorption. A drawback of the available literature data is that they provide at best 
indirect evidence of the intraluminal behavior of TDF in humans. We therefore decided to directly explore 
the intraluminal behavior of TDF by collecting and characterizing intestinal fluids from healthy volunteers 
after oral intake of TDF, in both fasting and fed condition. As demonstrated for other drugs, the parallel 
assessment of intraluminal and systemic concentrations may allow linking the intestinal behavior to the 
bioavailability of the drug. (Brouwers et al., 2007); (Brouwers and Augustijns, 2014) The specific aims of 
this study were (1) to investigate the in vitro degradation profile of TDF in fasted and fed state human 
intestinal fluids (FaHIF, FeHIF) in order to assess the risk for intestinal decomposition of ester prodrugs 
prior to absorption, (2) to explore the intraluminal behavior of TDF in healthy volunteers by collecting 
intestinal fluids after oral intake of TDF and (3) to investigate possible food effects on the intraluminal 
behavior of TDF.  
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2. MATERIALS AND METHODS 
2.1 Chemicals 
TDF was provided by the NIH AIDS Research and Reference Reagent Program (Germantown, MD). TFV was 
obtained from Watson International (Kunshan City, China). Dimethylsulfoxide (DMSO) and 
tetrabutylammonium sulfate were obtained from Acros-Organics (Geel, Belgium). Acetic acid was 
obtained from Chem-lab (Zedelgem, Belgium). Acetonitrile was purchased from Fisher Scientific 
(Leicestershire, UK). Monobasic potassium phosphate monohydrate (KH2PO4.H2O), bis-4-
nitrophenylphosphate, chloroacetaldehyde and pancreatin from porcine pancreas (powder, suitable for 
cell culture, 4× USP specifications) were obtained from Sigma–Aldrich (St. Louis, MO). Methanol and 
sodium acetate were purchased from VWR International (Leuven, Belgium). Water was purified with a 
Maxima system (Elga Ltd., High Wycombe Bucks, UK). All stock solutions were prepared in dimethyl 
sulfoxide. The mono-ester intermediate of TDF was obtained by degradation of TDF at neutral pH: a 
100µM solution of TDF was made in a phosphate buffer (pH 7); following chemical degradation during 7h 
at 60°C, an equal amount of 1M HCl was added to the solution; quantitative transformation into the 
intermediate without formation of TFV was confirmed.  
 
2.2 Stabilization mixture  
All samples taken during the experiments were diluted in a stabilization mixture to ensure the stability of 
the ester prodrug and mono-ester intermediate during further processing. The stabilization mixture 
consisted of MeOH:0.02N HCl (50:50) containing 400µM of the esterase inhibitor bis-
nitrophenylphosphate. 
 
2.3 In vitro stability studies 
2.3.1 Simulated intestinal fluids 
The in vitro degradation of TDF was investigated in mixtures of FaSSIF and FeSSIF containing 10 mg 
pancreatin/mL. The inclusion of pancreatin in FaSSIF has been reported by Borde et al. and the United 
States Pharmacopoeia 2009 to explore the degradation of ester prodrugs. (Borde et al., 2012); (“U.S. 
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Pharmacopeial Convention,” 2009) FaSSIF and FeSSIF were made according to the manufacturer’s 
preparation protocol (Biorelevant®, Croydon, UK) by dissolving SIF powder in an aqueous mixture of 
NaOH/NaH2PO4/NaCl for FaSSIF and NaOH/CH3COOH/NaCl for FeSSIF. The pH was adjusted to 6.5 for 
FaSSIF and to 5.0 for FeSSIF. After the addition of pancreatin, the solutions were centrifuged and the 
supernatant was used for stability studies. TDF (stock solution of 5mM in DMSO) was spiked into 1 mL of 
FaSSIF and FeSSIF resulting in a start concentration of 50µM. Samples were taken at predetermined time 
points and immediately diluted 100 times in the stabilization mixture. The diluted samples were 
centrifuged and the supernatant was used for analysis. 
 
2.3.2 Human intestinal fluids 
Fasted state human intestinal fluids (FaHIF) and fed state human intestinal fluids (FeHIF) were aspirated 
from four healthy volunteers (two males, two females, between 23 and 27 years old). The study was 
approved by the Committee of Medical Ethics of the University Hospitals Leuven, Belgium and the 
procedure followed the tenets of the Declaration of Helsinki. HIF were collected from the duodenum (D2–
D3) with a double-lumen polyvinyl catheter according to a previously described protocol. (Clarysse et al., 
2011) Samples were collected every 10 min for 120 min in the fasted state and for 90 min in the fed state. 
In the fed state, the nutritional drink Ensure Plus® was given to the volunteers. Pooled samples were 
made for each nutritional state, by combining equal volumes of the aspirates from all four volunteers. 
Pooled HIF were stored at −26◦C until further use. The pH amounted to 7.6 for the fasted state pool and 
to 5.5 for the fed state pool. 
For the stability studies, a DMSO stock solution of TDF (5mM) was spiked into 1mL of FaHIF/FeHIF 
generating a concentration of 50µM; this solution was incubated at 37°C for 1h. Every 15 min, a sample 
was taken and immediately diluted 100 times in the stabilization mixture. These samples were centrifuged 
and the supernatant was used for analysis. During the stability studies, the pH was measured using a 
Portamess 911 pH-meter (Knick GmbH & Company, Berlin, Germany). 
 
2.4 Clinical study 
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To study the intraluminal behavior of TDF in the fasted and the fed state in humans, a crossover study was 
performed in five healthy volunteers (aged between 22 and 26 years; two men and three women). The 
procedure followed the tenets of the Declaration of Helsinki and was approved by the Committee of 
Medical Ethics of the University Hospitals Leuven, Belgium. All volunteers provided written informed 
consent to participate in this study. After an overnight fast (>12 h), one double-lumen polyvinyl catheter 
[(Salem Sump Tube 14 Ch (external diameter 4.7 mm), Sherwood Medical, Petit Rechain, Belgium] was 
introduced via the nose and positioned into the duodenum (D2/D3). The position of the tube was checked 
by means of fluoroscopy. It has previously been reported that the presence of a transpyloric tube does 
not influence gastric emptying or duodenogastric reflux. (Müller-Lissner et al., 1982) For the experiments 
in the fasted state, a single tablet of Viread ® (300mg of TDF) was administered with 250ml of water. For 
the experiments in the fed state, 400 ml of a nutritional drink (Fortimel®) was given 20 min prior to intake 
of the TDF tablet. Fortimel (Nutricia, Strombeek-Bever, Belgium) was used to simulate a standard meal. 
One portion of 400 mL has an energy content of 2520 kJ, of which lipids, carbohydrates, and proteins 
constitute 32%, 41%, and 27% on energy basis, respectively; the osmolality amounts to 470 mOsm/kg; the 
pH is 6.8. Volunteers were asked to sit in upright position in a bed during the sampling procedure. 
Samples of human intestinal fluid (sample volume between 1.5 and 4 ml) were aspirated every 15 min up 
to 4h for both states. In parallel to the sampling of gastrointestinal fluids, venous blood samples were 
collected in heparinized tubes (BD Vacutainer systems, Plymouth, UK) at 0, 20, 40, 60, 80, 100, 120, 160, 
180, 210, 240, 300, 360, 420 and 480 min after drug intake. These blood samples were centrifuged at 
1,699 x g for 10 min to gain plasma samples which were stored at -26°C until further analysis. The 
intestinal samples were stabilized directly after collection by a 100-fold dilution in stabilization mixture 
(see section 2.2). After stabilization, the samples were stored at -26°C until further analysis. 
 
2.5 Analysis of TFV 
For the analysis of TFV, both plasma and intestinal samples were processed to obtain a fluorescent 
derivate of TFV. This derivatization was performed based on a previously described method. (Mallants et 
al., 2005); (Sparidans et al., 2003) In 200µL samples of plasma or stabilized dilutions of intestinal aspirates, 
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proteins were precipitated by adding 600 µl of methanol followed by vortexing (30 s). Supernatant 
obtained after centrifugation (20,817 x g, 10min) was transferred to new test tubes and evaporated under 
a gentle stream of air. The residue was redissolved in 200 µl of a buffer solution consisting of 100mM 
sodium acetate (pH 4.5) and 3.0% of the derivatizing agent chloroacetaldehyde. This solution was 
vortexed and kept at 80°C for 50min. In this way, tenofovir was converted into its fluorescent derivative 
(Naesens et al., 1992). The samples were cooled to -30°C for 5 min. After centrifugation at 20,817 x g for 
10 min, supernatant was collected and transferred into microvials to be analyzed by HPLC.  
 
After derivatization of the intestinal and plasma samples, concentrations of the fluorescent derivative of 
TFV were measured by reversed-phase HPLC and fluorescence detection. (Mallants et al., 2005) A volume 
of 30 µl was injected into a Waters HPLC system consisting of a 600E controller and pump, a 717plus 
autosampler and a Novapak C-18 column under radial compression (Waters, Milford, MA). Fluorescence 
signals (excitation 260 nm, emission 425 nm) were monitored with a Jasco FP-1520 fluorescence detector 
(Tokyo, Japan). Data acquisition and integration were performed using Empower Pro (Empower 2) 
(Waters, Belgium) software. The mobile phase consisted of a phosphate buffer (10 mM KH2PO4, 2 mM 
tetrabutylammonium sulfate, pH 8.0) (A) and acetonitrile (B). The flow rate amounted to 1.0mL/min. 
Separation was carried out with a gradient elution starting with 75% A and 25% B for 3.5 min, followed by 
a linear gradient from 25% to 90% B over 0.5 min, which was accompanied with a change in flow rate 
from 1mL/min to 1.5mL/min. After 7 min, the mobile phase was changed back to its initial conditions and 
the column was re-equilibrated during 7 min. The retention time of derivatised TFV was 4.5 min. 
Calibration curves in plasma and HIF were found to be linear in a concentration range of 0.03µM-1µM. 
The repeatability and precision were tested for the plasma and HIF samples at concentrations of 1µM and 
0.05µM, respectively. For both concentrations, the mean bias and variability were < 10%.  
 
2.6 Analysis of TDF and mono-ester 
Concentrations of TDF and its mono-ester intermediate in diluted intestinal samples were determined 
using HPLC with MS/MS detection. The Thermo Scientific (San Jose, USA) LCQ Deca XP Max iontrap mass 
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spectrometer system equipped with an electrospray ionization (ESI) source was used. Data acquisition 
and peak integration were performed with Xcalibur®. A Kinetex® XB-C18 column (length 50mm × 2.1mm, 
particle size 2.6µm) (Phenomenex, The Netherlands), protected by a Krudkatcher Ultra HPLC In-Line filter 
(Phenomenex), was used for chromatographic separation. The mobile phases consisted of 0.2% formic 
acid (A), 5mM ammonium acetate buffer (pH4.8) (B) and acetonitrile (C). The flow rate amounted to 200 
µL/min. Separation was carried out with a gradient elution starting with 81% A, 9% B and 10% C, changing 
to 55.5% A, 10.5% B, 34% C after 1 min. After 2 min the composition changed immediately to 30% A, 10% 
B, 60% C. After 2.5min, the column was re-equilibrated with the initial conditions for 3min. The total run 
time was 8.5min and the injection volume amounted to 20µL (full loop mode). The mass spectrometer 
was operated in the positive electrospray (ESI) mode for TDF and in the negative ESI mode for the mono-
ester. The spray voltage, capillary voltage and capillary temperature were 4.50kV, 12V and 325°C, 
respectively. Nitrogen was used as the sheath gas (59 arbitrary units), ion sweep and auxillary gas (20 
arbitrary units). Argon was used as the collision gas at a pressure of 1.5mTorr. The mass spectrometer was 
operated in the selected reaction monitoring (SRM) mode. A single precursor–product ion pair was used 
for detection: m/zTDF 520.20 → 288.0 (collision energy: 32V) and m/zMono 402.10 → 328.00 (collision 
energy: 32V), both with a scan time of 100ms. Calibration curves were linear over the concentration range 
of 0.03 to 1µM. The repeatability and precision for TDF and its mono-ester intermediate were assessed at 
a concentration of 0.3µM. Repeatability and precision errors were found to be < 10% for both 
compounds. 
 
2.7 Data presentation and Statistical Analysis  
All concentration-time profiles obtained from the in vitro studies are presented as mean±sd for three 
experiments. All concentration-time profiles from the clinical trial are presented as mean±sem for five 
subjects. A paired t-test was used to compare selected parameters (AUC0-4h and AUC0-8h) of the in vivo 
concentration-time profiles between the fasted and fed state condition. When p < 0.05, differences were 
considered statistically significant.  
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3. RESULTS AND DISCUSSION 
 
The in vitro Caco-2 system as well as the rat in situ intestinal perfusion setup have suggested that 
premature intestinal degradation of TDF into TFV may limit the efficiency of the prodrug approach. 
(Barditch-crovo et al., 2001); (Heimbach et al., 2003); (Roux et al., 2013); (Van Gelder et al., 1999); (Van 
Gelder et al., 2000); (Van Gelder, 2000); (Gelder et al., 2002) In this study, we further explored the 
intraluminal stability of the ester prodrug using biorelevant approaches, including in vitro as well as in 
vivo methods. In a first set of experiments, the in vitro stability of TDF in simulated and human intestinal 
fluids was determined; subsequently, the in vivo behavior was explored in humans. (Borde et al., 2012) 
 
3.1 In vitro studies 
3.1.1 Simulated intestinal fluids 
As suggested by United States Pharmacopoeia 2009 and similar to Borde et al., FaSSIF was supplemented 
with 10mg pancreatin per mL to explore the degradation of ester prodrugs. (Borde et al., 2012); (“U.S. 
Pharmacopeial Convention,” 2009) When TDF was spiked in this solvent system, almost all TDF was 
degraded within 60 min resulting in the formation of mono-ester intermediate and tenofovir (figure 2). 
For the fed state, FeSSIF was supplemented with 10 mg pancreatin per mL. The pH of FeSSIF was not 
influenced by the addition of pancreatin powder. When adding TDF to this mixture, TDF slowly degraded, 
resulting in the formation of the mono-ester intermediate; however, no formation of tenofovir could be 
observed (figure 2), suggesting less chemical and/or enzymatic degradation in fed state conditions. This 
reduced degradation might be attributed to the lower pH of FeSSIF (5.0 versus 6.5 in FaSSIF) and/or 
possible increased micellar entrapment of the hydrophobic TDF (logD5.5=2.29) in TDF which may result in a 
shielding effect of the micelles.  
 
3.1.2 Human intestinal fluids  
Preliminary experiments showed no degradation of TDF in human gastric fluids obtained in both fasted 
and fed state conditions; therefore stability was only studied in human intestinal fluids obtained in the 
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fasted (FaHIF) as well as the fed state (FeHIF). Upon addition of TDF to FaHIF, TDF converted rapidly to 
mono-ester and TFV, resulting in complete degradation within one hour (figure 3). From a qualitative 
point-of-view, the observed TDF degradation in FaSSIF supplemented with pancreatin (figure 2) mimicked 
TDF degradation in FaHIF. In line with Borde et al. (Borde et al., 2012), however, the degradation rate was 
higher in human versus simulated fluids. Upon addition of TDF to FeHIF, a slow decrease of the TDF 
concentration was observed, resulting in the formation of the mono-ester intermediate but not TFV. 
Similar as for TDF in FeSSIF, this slower degradation can be due to (1) lower pH (5.5 versus 7.6) and (2) 
micellar entrapment. In addition, food-induced inhibition of enzymatic degradation may result in a higher 
stability of the prodrug. Similar to the fasted state, an underestimation of degradation was observed in 
pancreatin supplemented FeSSIF compared to FeHIF; however, the qualitative profile was the same, i.e. 
the formation of mono-ester intermediate but no tenofovir.  
 
3.2 In vivo study 
In a next step, we wanted to explore whether these in vitro results are representative for the in vivo 
situation. To the best of our knowledge, no intraluminal in vivo data is available about the intestinal 
behavior of ester prodrug. Therefore, a clinical study was performed in which one tablet of TDF (Viread®, 
300 mg) was given to healthy volunteers in the fasted as well as the fed state. Subsequently, intestinal 
fluids from the duodenum were aspirated and analyzed. In parallel to the intestinal sampling, blood 
samples were collected to link the intestinal behavior of TDF to the appearance of tenofovir in the 
systemic circulation. A similar approach was already successfully applied to investigate the intestinal 
behavior of fosamprenavir and posaconazole. (Brouwers et al., 2006); (Walravens et al., 2011)  
 
3.2.1 Plasma concentration-time profiles 
Figure 4 shows the mean plasma concentration of TFV as a function of time after oral administration of 
one Viread® tablet containing 245 mg of TDF in fasted and fed state conditions. In plasma, no prodrug nor 
mono-ester intermediate could be observed (data not shown), suggesting quantitative degradation of TDF 
during absorption and/or first pass metabolism. In the fasted state, absorption appeared to be very fast 
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with a maximum plasma concentration of 978±183nM obtained after 28±5min. The maximum plasma 
concentration of TFV in the fed state was observed after 132±32min, with a lower Cmax of 711±162nM as 
compared to fasted state conditions. AUC 0-8h and Cmax did not significantly differ between fasted 
(151±208µM∙min; 978±183nM) and fed (148±394µM∙min; 771±162nM) state conditions; however, tmax 
was significantly increased in fed state conditions. While the increase in tmax was in line with literature, 
our study did not reveal a positive food effect on the bioavailability of TFV. (Barditch-crovo et al., 2001) It 
should be mentioned, however, that the positive food effect reported in literature (25% bioavailability in 
the fasted state versus 40% in the fed state) was demonstrated after a daily treatment of 23 days, which 
makes it difficult to compare with our single dose study. (Barditch-crovo et al., 2001) To further 
investigate the difference in concentration-time profile between the fasted and fed state, the intraluminal 
behavior of TDF was assessed by the simultaneous collection of intestinal fluid samples.  
 
3.2.2 Intestinal concentration-time profiles 
For the collection of the intestinal fluids, a unique sampling method was used whereby one double-lumen 
polyvinyl catheter was placed via the nose into the duodenum. After the placement of the catheter and 
the intake of TDF, intestinal fluids were collected and analyzed for TDF, mono-ester intermediate and TFV. 
 
3.2.2.1 Fasted state condition 
The concentrations of TDF, mono-ester intermediate and TFV observed in the duodenum are depicted in 
figure 5 and confirm that rapid degradation is taking place in the intraluminal environment. In the fasted 
state condition, the mean maximum concentration of TDF (163±71µM) was reached 24±4min after the 
intake of the drug. Similar to the in vitro studies (figures 2 and 3), degradation resulted in the formation of 
both the mono-ester intermediate and tenofovir. The mono-ester intermediate reached a mean 
maximum concentration of 193±63µM 33±9min after intake of the drug. The higher concentration of the 
mono-ester intermediate compared to the prodrug can probably be attributed to the dual fate of TDF, i.e. 
the prodrug may be (1) degraded to its mono-ester intermediate, and (2) rapidly absorbed in the non-
ionized state (logD7.4= 2.65 ). Rapid absorption of TDF is confirmed by the short tmax observed for TFV in 
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the plasma profiles (figure 4), which corresponds to the relatively short tmax of TDF in intestinal samples. In 
contrast, the intermediate is not expected to be absorbed due to its negative charge (logD7.4=-1.54). In the 
fasted state, the mean pH of the intestinal fluids was 6.65±0.52 which is in agreement with reported data 
in the literature (pH between 6.3 and 7.5). (Augustijns et al., 2013) Based on the findings that ester 
prodrugs are exponentially more sensitive to chemical hydrolysis at a pH>4, chemical degradation cannot 
be neglected. (Lung-Chi et al., 2001) Also the active compound TFV could be detected in the intestinal 
samples demonstrating phosphodiesterase activity; no clear Cmax could be observed, with an average 
concentration fluctuating around 75µM.  
 
3.2.2.2 Fed state condition 
TDF, the mono-ester intermediate and TFV were also detected in the intestinal samples collected in fed 
state conditions (figure 6). The combination with food induced a delay in gastric emptying, resulting in 
increased tmax values and smoother profiles for TDF and its degradation compounds. The concentration of 
TDF reached its mean maximum concentration (210±26µM) 60±7.3min after drug intake. This differs 
significantly (p<0.05) from tmax of TDF observed in the fasted state condition (24±4min). The mean 
maximum concentration of the mono-ester intermediate amounted to 339±40µM, and was reached 
84±14min after intake of the tablet. The AUC 0-4h of TDF and the mono-ester were both significantly higher 
in fed versus fasted state.  The 3-fold increase in AUC 0-4h of TDF (fed: 13.9±2.1µM∙min versus fasted: 
4.1±1.5µM∙min) suggests a slower absorption of TDF in fed state conditions. A food-induced delay in 
gastric emptying and reduction of the absorption rate is reflected in the plasma concentration-time 
profiles for TFV (figure 4). For TFV, average concentrations fluctuated around 12µM; the concentration is 
much lower compared to the fasted state condition indicating a higher intestinal stability of the mono-
ester intermediate in the fed state.  
When considering the ratio of mono-ester intermediate to prodrug, it appears that there is relatively 
more mono-ester intermediate present in fasted state conditions than in fed state conditions (figure 7). 
These results indicate slower degradation of TDF in combination with a reduced rate of absorption in 
postprandial conditions.   
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Interestingly, the higher intestinal concentrations of TDF in fed state conditions are not accompanied by 
higher concentrations in the plasma-concentration profile (figure 4), which suggests that the 
concentrations measured do not reflect the driving force for absorption. It has been mentioned before 
that micellar entrapment of the prodrug may occur in view of the relatively high lipophilicity of the ester 
prodrug. Dialysis experiments were performed to explore the association of TDF with micelles; 
unfortunately, degradation in the media used prevented us to estimate micellar entrapment. 
Compared to the observed in vitro degradation profile of TDF, the clinical study confirmed the faster 
conversion of TDF to mono-ester intermediate in fasted versus fed state conditions. In fasted state 
conditions, further degradation to TFV was observed both in vitro and in vivo. In fed state conditions, 
however, the formation of intraluminal TFV in vivo (albeit significantly less than in fasted state) could not 




The ester prodrug TDF, which has been designed to overcome permeability issues of tenofovir, has a 
relatively low bioavailability of 25% in man. In the present study we explored whether the limited 
efficiency of the prodrug is due to premature degradation in the intestinal tract. Based on in vitro studies 
performed in biorelevant media, the following conclusions could be made: (1) TDF does not degrade in 
the stomach due to the absence of esterases (enzymatic stability) and the acidic pH (chemical stability), 
(2) in fasted state conditions, TDF is rapidly converted to mono-ester intermediate and TFV, and (3) in fed 
state conditions, the degradation rate of TDF is reduced compared to the fasted state. The clinical study 
confirmed extensive intraluminal degradation of TDF in healthy volunteers. Similar to the in vitro 
experiments, the ester prodrug was more stable in the fed state condition compared to the fasted state 
condition. However, the increased intraluminal stability of the prodrug in postprandial conditions was not 
reflected in enhanced systemic exposure of TVF. Micellar encapsulation in the intestine may decrease the 
free concentration as driving force for absorption, and thereby counteract the improved prodrug stability.  
The results of this study reveal extensive premature degradation of TDF; therefore, tenofovir may benefit 
from a new prodrug approach. Since fast absorption may (partly) compensate for fast degradation, 
prodrug selection should be based on (combined) stability and permeability assays. 
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5. FIGURE LEGENDS 
Figure 1: Degradation profile of TDF. 
 
Figure 2: Time-dependent degradation of tenofovir disoproxil fumarate (●) (at initial concentration of 
50µM) to mono-ester intermediate (■) and tenofovir (▲) in FaSSIF with 10mg pancreatin/mL (A) and 
FeSSIF with 10mg pancreatin/mL (B). Results are expressed as mean±sd (n=3). 
 
Figure 3: Time-dependent degradation of tenofovir disoproxil fumarate (●) (at initial concentration of 
50µM) to mono-ester intermediate (■) and tenofovir (▲) in FaHIF (A) and FeHIF (B). Results are 
expressed as mean±sd (n=3). 
 
Figure 4: Plasma concentration-time profiles for TFV in the fasted state (A) and fed state (B) after oral 
administration of a tablet containing 245 mg TDF. Results are expressed as mean±sem (n=5).  
 
Figure 5: Duodenal concentration-time profile for TDF (A), mono-ester (B) and TFV (C) in the fasted state 
after oral administration of a tablet containing 245 mg TDF. Results are expressed as mean±sem (n=5). 
 
Figure 6: Duodenal concentration-time profile for TDF (A), mono-ester (B) and TFV (C) in the fed state 
after oral administration of a tablet containing 245 mg TDF. Results are expressed as mean±sem (n=5). 
 
Figure 7: Ratio of the concentration of mono-ester intermediate over the concentration of TDF in function 
of time in fasted (●) and fed (■) state condition after oral administration of a tablet containing 245 mg 
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